Advancements in Cancer Immunotherapies

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

(2022) Hirohito Yamaguchi et al.   Nature Reviews Clinical Oncology

Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives

(2022) Suheil Albert Atallah-Yunes et al.   Frontiers in Immunology

Tumor Selective Metabolic Reprogramming as a Prospective PD‐L1 Depression Strategy to Reactivate Immunotherapy

(2022) Yu Liu et al.   ADVANCED MATERIALS

Metformin modified chitosan as a multi-functional adjuvant to enhance cisplatin-based tumor chemotherapy efficacy

(2022) Zaigang Zhou et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

(2022) Qing Wu et al.   Journal of Hematology & Oncology

Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition

(2022) McKenzie Crist et al.   Journal for ImmunoTherapy of Cancer

Metabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy

(2022) Zaigang Zhou et al.   JOURNAL OF CONTROLLED RELEASE

Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles

(2021) Zhaohan Wei et al.   Nature Communications

Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy

(2021) Wei Xiong et al.   ACS Applied Materials & Interfaces

Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade

(2021) Xiaoming Dai et al.   MOLECULAR CELL

FDA approves 100th monoclonal antibody product

(2021) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

CAR-T cell therapy: current limitations and potential strategies

(2021) Robert C. Sterner et al.   Blood Cancer Journal

PD-L1 regulation revisited: impact on immunotherapeutic strategies

(2021) Giulia Lucibello et al.   TRENDS IN MOLECULAR MEDICINE

Chitosan oligosaccharide regulates AMPK and STAT1 pathways synergistically to mediate PD-L1 expression for cancer chemoimmunotherapy

(2021) Jiashe Chen et al.   CARBOHYDRATE POLYMERS

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action

(2021) Timothée Olivier et al.   JAMA Network Open

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

(2020) Maud Mayoux et al.   Science Translational Medicine

Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial

(2020) Shuhong Wang et al.   CLINICAL CANCER RESEARCH

Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy

(2020) Daria S. Chulpanova et al.   Frontiers in Cell and Developmental Biology

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

(2020) Rilan Bai et al.   Biomarker Research

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

(2019) Martin Reck et al.   Lancet Respiratory Medicine

Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures

(2019) Dongqiang Zeng et al.   Cancer Immunology Research

PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy

(2019) Xinyi Tu et al.   MOLECULAR CELL

Doxorubicin inhibits PD-L1 expression by enhancing TTP-mediated decay of PD-L1 mRNA in cancer cells

(2019) Dong Jun Kim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Engineered T Cell Therapy for Cancer in the Clinic

(2019) Lijun Zhao et al.   Frontiers in Immunology

Next generation of immune checkpoint therapy in cancer: new developments and challenges

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Cytokines in the Treatment of Cancer

(2018) Kevin C. Conlon et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

(2018) David F. McDermott et al.   NATURE MEDICINE

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell–induced CSF1 promotes melanoma resistance to PD1 blockade

(2018) Natalie J. Neubert et al.   Science Translational Medicine

Current status and future directions of cancer immunotherapy

(2018) Hongming Zhang et al.   Journal of Cancer

Next generation immune-checkpoints for cancer therapy

(2018) Chiara Donini et al.   Journal of Thoracic Disease

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors

(2018) Shifaa Abdin et al.   Cancers

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

(2018) Judith A. Seidel et al.   Frontiers in Oncology

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

(2018) Jong-Ho Cha et al.   MOLECULAR CELL

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Tumor Antigen Escape from CAR T-cell Therapy

(2018) Robbie G. Majzner et al.   Cancer Discovery

Cytokines in clinical cancer immunotherapy

(2018) Pedro Berraondo et al.   BRITISH JOURNAL OF CANCER

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

(2018) Moshe Sade-Feldman et al.   CELL

Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells

(2018) John P. Murad et al.   Frontiers in Immunology

Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy

(2018) Maiko Matsushita et al.   Journal of Oncology

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

(2017) C S Chim et al.   LEUKEMIA

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

The immune contexture in cancer prognosis and treatment

(2017) Wolf H. Fridman et al.   Nature Reviews Clinical Oncology

Tumour-associated macrophages as treatment targets in oncology

(2017) Alberto Mantovani et al.   Nature Reviews Clinical Oncology

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

(2017) Mizuki Nishino et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

(2017) Sean P. Arlauckas et al.   Science Translational Medicine

Emerging targets in cancer immunotherapy

(2017) Samantha Burugu et al.   SEMINARS IN CANCER BIOLOGY

Human Tumor Antigens Yesterday, Today, and Tomorrow

(2017) Olivera J. Finn   Cancer Immunology Research

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

(2017) Kristen M. Hege et al.   Journal for ImmunoTherapy of Cancer

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients

(2016) J. Fucikova et al.   BLOOD

Lymphocyte-activation gene-3, an important immune checkpoint in cancer

(2016) Yayi He et al.   CANCER SCIENCE

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma

(2016) Wei-Wei Deng et al.   OncoImmunology

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy

(2016) Maarten Swart et al.   Frontiers in Oncology

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer

(2015) E. M. Dijkgraaf et al.   ANNALS OF ONCOLOGY

Innate Immune Recognition of Cancer

(2015) Seng-Ryong Woo et al.   Annual Review of Immunology

Targeting HER2 for the Treatment of Breast Cancer

(2015) Mothaffar F. Rimawi et al.   Annual Review of Medicine

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

Cancer immunotherapy: harnessing the immune system to battle cancer

(2015) Yiping Yang   JOURNAL OF CLINICAL INVESTIGATION

Alkylating Agent Melphalan Augments the Efficacy of Adoptive Immunotherapy Using Tumor-Specific CD4+T Cells

(2015) Xiaoyun Lu et al.   JOURNAL OF IMMUNOLOGY

CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin

(2015) R. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

(2015) Sebastian Kreiter et al.   NATURE

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Immunogenicity of somatic mutations in human gastrointestinal cancers

(2015) E. Tran et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Immune checkpoint inhibitors: a new frontier in bladder cancer

(2015) Max Kates et al.   WORLD JOURNAL OF UROLOGY

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma

(2015) Baoan Chen et al.   Drug Design Development and Therapy

Immune modulation for cancer therapy

(2014) J Naidoo et al.   BRITISH JOURNAL OF CANCER

Immune Response and the Tumor Microenvironment: How They Communicate to Regulate Gastric Cancer

(2014) Keunwook Lee et al.   Gut and Liver

Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity

(2014) Fei Duan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

(2014) Mahesh Yadav et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

(2014) Nicolas J. Llosa et al.   Cancer Discovery

Treg and CTLA-4: Two intertwining pathways to immune tolerance

(2013) Lucy S.K. Walker   JOURNAL OF AUTOIMMUNITY

PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells

(2013) Erin E. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

Microenvironmental regulation of tumor progression and metastasis

(2013) Daniela F Quail et al.   NATURE MEDICINE

Concise Drug Review: Azacitidine and Decitabine

(2013) E. J. B. Derissen et al.   ONCOLOGIST

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

Exploiting the Mutanome for Tumor Vaccination

(2012) J. C. Castle et al.   CANCER RESEARCH

Densely Granulated Murine NK Cells Eradicate Large Solid Tumors

(2012) R. B. Liu et al.   CANCER RESEARCH

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

The application and biology of immunomodulatory drugs (IMiDs) in cancer

(2012) Beiqing Pan et al.   PHARMACOLOGY & THERAPEUTICS

A review of the history, properties, and use of the immunomodulatory compound lenalidomide

(2011) Jerome B. Zeldis et al.   Annals of the New York Academy of Sciences

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

(2011) Nicolas F Delahaye et al.   NATURE MEDICINE

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

(2010) R. H. Vonderheide et al.   CLINICAL CANCER RESEARCH

Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma

(2010) H. Miles Prince et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

(2010) Ralf Lutterbuese et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nodal Lymphangiogenesis and Metastasis

(2009) Satoshi Hirakawa et al.   AMERICAN JOURNAL OF PATHOLOGY

Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells

(2009) J. F. Grosso et al.   JOURNAL OF IMMUNOLOGY

Vascular Endothelial Growth Factor C Facilitates Immune Tolerance and Endovascular Activity of Human Uterine NK Cells at the Maternal-Fetal Interface

(2009) S. S. Kalkunte et al.   JOURNAL OF IMMUNOLOGY

Expression of SDF-1α and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer

(2008) N Yoshitake et al.   BRITISH JOURNAL OF CANCER

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways

(2008) Brian T. Fife et al.   IMMUNOLOGICAL REVIEWS

A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions

(2008) C. Grutter et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA